Spyre Therapeutics (SYRE) EPS (Basic) (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly EPS (Basic) came in at -$0.88 in Q1 2026, down 18.25% YoY from -$1.07 in Q1 2025, and up 10.01% on a QoQ basis from -$0.98 in Q4 2025.
Powered by 
Analysis
Spyre Therapeutics (SYRE) EPS (Basic) (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of EPS (Basic) data on file, last reported at -$0.88 in Q1 2026.
- Quarterly EPS (Basic) fell 18.25% year-over-year to -$0.88 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.28 (up 34.11% YoY) and the FY2025 annual result came in at -$2.42, up 45.22% from the prior year.
- EPS (Basic) grew to -$0.88 in Q1 2026, from -$0.98 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$0.19 in Q3 2025 to a low of -$56.79 in Q2 2023.
- A 5-year average of -$6.74 and a median of -$1.36 in 2024 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2023 — EPS (Basic) tumbled 736.55% — and 2024, when it soared 98.49%.
- Tracing SYRE's EPS (Basic) over 5 years: stood at -$5.58 in 2022, then slumped by 64.07% to -$9.16 in 2023, then jumped by 86.93% to -$1.2 in 2024, then climbed by 18.45% to -$0.98 in 2025, then gained by 10.01% to -$0.88 in 2026.
- The last three EPS (Basic) figures came in at -$0.88 (Q1 2026), -$0.98 (Q4 2025), and -$0.19 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -3.06 |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 0.18 |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -0.06 |
| 10 | Spyre Therapeutics | 7.39 Bn | 7.39 Bn | - | -0.43 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.43 |
| Mar 31, 2026 | -0.88 |
| Dec 31, 2025 | -0.97 |
| Sep 30, 2025 | -0.18 |
| Jun 30, 2025 | -0.60 |
| Mar 31, 2025 | -0.74 |
| Dec 31, 2024 | -1.19 |
| Sep 30, 2024 | -1.35 |
| Jun 30, 2024 | -0.85 |
| Mar 31, 2024 | -1.18 |
| Dec 31, 2023 | -8.61 |
| Sep 30, 2023 | -9.34 |
| Jun 30, 2023 | -56.79 |
| Mar 31, 2023 | -4.89 |
| Dec 31, 2022 | -5.58 |
| Sep 30, 2022 | -4.84 |
| Jun 30, 2022 | -6.79 |
| Mar 31, 2022 | -9.26 |
| Dec 31, 2021 | -7.77 |
| Sep 30, 2021 | -7.72 |